Upstate Active Clinical Trials Seeking Participants
ECOG E1505:A Phase III Randomized Trial of Adjuvant Chemotherapy with or Without Bevacizumab for Patients with Completely Resected Stage IB (> 4 cm) -IIIA Non-Small Cell Lung Cancer (NSCLC)
What is the purpose of the study?
This research is being done because even with the most aggressive after-surgery treatment with chemotherapy, many people still have the lung cancer recur (come back). The purpose of this study is to determine if adding the new drug bevacizumab to chemotherapy improves the chance for cure for patients who have had surgery for the removal of the lung cancer. We will compare the effects (good and bad) of adding bevacizumab to chemotherapy with standard chemotherapy alone on subjects and their lung cancer to see which is better at preventing the cancer from coming back.
Who is eligible?
Diagnosis of stage IB-IIIA non-small cell lung cancer that has been surgically removed within the last 6-12 weeks, no prior treatment, no uncontrolled high blood pressure, adequate bone marrow, kidney and liver function tests, good general health.
What is involved if I participate?
- How long is the study?
Chemotherapy will last for approximately 12 weeks. Subjects randomized to receive Bevacizumab with their chemotherapy will continue to receive Bevacizumab for up to one year. The physicians would like to keep track of subject's medical condition for a period of 10 years after entering the study, to look at the long-term effects of the treatment.
- Is transportation provided or reimbursed?
- Is parking provided or reimbursed?
- What tests and procedures are involved?
Medical history and physical exam, EKG, Blood tests, Blood pregnancy test, urinalysis, chest x-ray and CT scans. In addition, you will be asked to fill out brief forms with questions about your smoking status.
Who is the doctor administering the study?
Stephen Graziano, MD
Where will the study take place?
University Hospital, Satellite offices in Oswego, Oneida and Hill Medical Center
Over what time period is the study scheduled to run?
6/2007 to ongoing
Who can I contact for more information?
- Name: Ginny Schutt
- Phone: 315-464-8230
- Email: firstname.lastname@example.org
- Fax: 315-464-8280
If you are interested in this trial, please contact the study coordinator or investigator noted above.